Please type a plus sign (+) inside this b

UTILITY PATENT APPLICATION

TRANSMITTAL

07-10-01

PTO/SB/05 (2/98) ed for use through 09/30/2000. OMB 0651-0032

ark Office: U.S. DEPARTMENT OF COMMERCE

PC10782A Attorney Docket No. First Named Inventor or Application Identifier

Title

S. McLean

USE OF DELTA OPIOID RECEPTOR LIGANDS AND SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF CHEMICAL DEPENDENCIES

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))	(press Mai	l Label No.	EL44640227	5US 60 =			
	— Т		Assista	at Commissioner for Batanta			
APPLICATION ELEMENTS		ADDR		nt Commissioner for Patents.			
See MPEP chapter 600 concerning utility patent application contents.				gton, DC 20231			
1. *Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)		6.	Microfiche Computer Prog	gram (Appendix)			
2. Specification [Total Pages 19]		7. Nucleo	otide and/or Amino Acid S	equence Submission			
(preferred arrangement set forth below)		(іг арр	licable, all necessary)				
- Descriptive title of the Invention		a.	Computer Readal	blo Conv			
- Cross References to Related Applications		a.		,			
- Statement Regarding Fed sponsored R&D		b.	Paper Copy (iden	tical to computer copy)			
- Reference in Microfiche Appendix		C.	Statement verifyir	ng identity of above copies			
- Background of the Invention	Г	ACCOMPANYING APPLICATION PARTS					
- Brief Summary of the Invention				,			
 Brief Description of the Drawings (if filed) 		8.	Assignment Papers (cove	er sheet & document(s))			
Detailed DescriptionClaim(s)			37 C.F.R. §3.73(b) Stateme (when there is an assigne				
- Abstract of the Disclosure		<u> </u>	English Translation Docu	·			
		一	_	` 			
3. Drawing(s) (35 U.S.C. 11.3)[Total sheets	1		Information Disclosure Statement (IDS)/PTO-144	Copies of IDS Citations			
4. Oath or Declaration [Total pages 3		12.	Preliminary Amendment				
a. Newly executed (original or copy)		13.	Return Receipt Postcard	(MPEP 503)			
b. Copy from a prior application (37 CFR			(Should be specifically ite	mized)			
§1.63(d))	1	14.	*Small Entity St	atement filed in prior application,			
(for continuation/divisional with Box 17 completed)			, —	itus still proper and desired			
[Note Box 5 below]			(PTO/SB/09-12)				
i. DELETION OF INVENTOR(S)		15.	Certified Copy of Priority I	Document(s)			
Signed statement attached deleting			(if foreign priority is claime	• •			
inventor(s) named in the prior application,							
see 37 C.F.R. §§1.63(d)(2) and 1.33(b)							
5 Incorporation By Reference (useable if Box 4b is o		16.	Other: Priority Claim				
The entire disclosure of the prior application, from whic copy of the oath or declaration is supplied under Box 4			60/217,548				
considered to be part of the disclosure of the accompa		July 12, 2000					
application and is hereby incorporated by reference therein.		Suly 12, 2000					
	L						
*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27). EXCEPT							
	<u> </u>		N A PRIOR APPLICATION IS REL				
17. If a CONTINUING APPLICATION, check appropriate b	ox, and supp	oly the requisite	e information below and in a p	oreliminary amendment:			
Continuation Divisional Cor	ntinuation-i	n-part (CIP)	of prior application	on No:/			
Prior application information: Examiner			Group/Art Unit:				
18. CORRESPONDENCE ADDRESS							
Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or Correspondence address below							
Name Paul H. Ginsburg							
Address Pfizer Inc							
Address 235 East 42nd Street, 20th Floor							
City New York State		New York	Zip Code	10017-5755			
Country United States Of America Telephon	ie	(212)573-		(212)573-1939			
NAME (Print/type) Seth H. Jacobs			No. (Attorney/Agent)	32,140			
Call	<u></u>	-gionanon					
Signature Sold (144)			Date	779/6/			

						PTO/SB/17(2/9
			OMB 065	1-0032 Pa	Approved for use the Trademark Office: U.S. DEPARTMENT	T OF COMMERC
					ete if Known	
FEE TRANSMITTAL	Applica	Application Number			Unassigned	
	Filing (Filing Date			Concurrent herewith	
Patent fees are subject to annual revision on October 1.	First Named Inventor S. McLean		S. McLean			
These are the fees effective October 1, 1997. Small Entity payments must be supported by a small entity statement,	Examiner Name Unassigned					
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.	Group/Art Unit Unassigned					
See 37 C.F.R. §§ 1.27 and 1.28. Total Amount of Payment (\$) 710.00	Group/Art Unit Unassigned Attorney Docket No. PC10782A					
	Attorne	by Docke				
METHOD OF PAYMENT (check one)	2 4000	TIONIAL E		FEE CA	ALCULATION (continued)	
The commissioner is hereby authorized to charge indicated from and availt any over neumants to:		3. ADDITIONAL FEES Large Entity Small Entity				
indicated fees and credit any over payments to: Deposit	Fee	Fee	Fee	Fee		
Account Number 16-1445	Code	(\$)	Code	(\$)	Fee Description	Fee Paid
Danasia						
Deposit Account Name Pfizer Inc	105	130	205	65	Surcharge – late fee or oath	
	127	50	227	25	Surcharge-late provisional filing fee or	
Charge Any Additional Fee Required Under Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing	400	400	400	400	cover sheet	
37 C.F.R. §§ 1.16 and 1.17. of the Notice of Allowance.	139	130	139	130	Non-English specification	
·	147	2,520	147	2,520	For filing a request for reexamination	
2. Payment Enclosed:	112	920*	112	920*	Requesting publication of SIR prior to	
☐ Check ☐ Money Order ☐ Other	113	1,840*	113	1,840*	Examiner action Requesting publication of SIR after Examiner action	
FEE CALCULATION	115	110	215	55	Extension for reply within first month	
I. BASIC FILING FEE	116	390	216	195	Extension for reply within second month	
Laura Entite Constitution	117	890	217	445	Extension for reply within third month	
Large Entity Small Entity Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	118	1,390	218	695	Extension for reply within fourth month	
101 710 201 355 Utility filing fee 710.00	128	1,890	228	945	Extension for reply within fifth month	
106 320 206 160 Design filing fee	119	310	219	155	Notice of Appeal	
107 490 207 245 Plant filing fee	120	310	220	155	Filing a brief in support of an appeal	
108 710 208 355 Reissue filing fee	121	270	221	135	Request for oral hearing	
114 150 214 75 Provisional filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$) 710.00	140	110	240	55	Petition to revive - unavoidable	
2. EXTRA CLAIM FEES	141	1,240	241	620	Petition to revive - unintentional	
Extra Fee from	142	1,240	242	620	Utility issue fee (or reissue)	
Claims below Fee Paid otal Claims 10 -20***= 0 X 10 = 0	143	440	243	220	Design issue fee	
ndependent - 3**= X =	144	600	244	300	Plant issue fee	
Aultiple Dependent = 0	122	130	122	130	Petitions to the Commissioner	
or number previously paid, if greater; For Reissues, see below	123	50	123	50	Petitions related to provisional	
Large Entity Small Entity Fee Fee Fee Fee Description	126	240	126	240	applications Submission of Information Disclosure	
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581	40	581	40	Statement Recording each patent assignment pe	,
102 80 40 Independent claims in excess of 3	146	710	246	355	property (times number of properties) Filing a submission after final rejection	L1

SUBTOTAL (2) (\$) *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) SUBMITTED BY Complete (if Applicable) Type or Printed Name Seth H. Jacobs Reg. Number 32,140 Signature Deposit Account User ID

149

710

Other Fee (specify)

Other Fee (specify)

249

355

104

109

110

270

80

18

135

40

202

204

209

210

Multiple dependent claim, if not paid

**Reissue independent claims over original patent **Reissue claims in excess of 20 and

over original patent

(37 CFR 1.129(a))
For each additional invention to be

examined (37 CFR 1.129(b))

PFIZER DOCKET NO: PC10782A/SHJ
APPLICATION NUMBER: NOT YET ASSIGNED
TITLE: USE OF DELTA OPIOID RECEPTOR LIGANDS AND SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF CHEMICAL DEPENDENCIES
APPLICANT: S. McLean et al
"Express Mail" mailing label number <u>EL446402275US</u>
Date of Deposit July 9, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.
Michelle D. Dungee
(Signature of person mailing paper or fee)

Pfizer, Inc Patent Department, 20th Floor 235 East 42nd Street New York, NY 10017-5755 (212) 733-3189